Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Long Term Safety Trial of BI 655130 (SPESOLIMAB) Treatment in Patients With Moderate to Severely Active Ulcerative Colitis Who Have Completed Previous BI 655130 Trials

NCT03648541 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03648541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03648541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Long Term Safety Trial of BI 655130 (SPESOLIMAB) Treatment in Patients With Moderate to Severely Active Ulcerative Colitis Who Have Completed Previous BI 655130 Trials
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
October 29, 2018
Completion date
May 3, 2023
Enrollment
79 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative